NFKB1 and inflammatory bowel disease: Mechanistically, cardamonin blocked NF-κB and MAPK signaling pathways, including inhibition of NF-κB p65 nuclear translocation and downstream target gene expression, demonstrating its potential as a therapeutic agent for IBD.